Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 first-line pembrolizumab plus sacituzumab govitecan maintenance study in extensive-stage small cell lung cancer
MOH_2024-07-23_013545Phase 2Recruiting
- Sponsor
- Shaare Zedek Medical Center
- Start
- Jun 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, sacituzumab govitecan, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by Shaare Zedek Medical Center. Primary endpoint: Progression-free survival. Started Jun 2024; status: recruiting.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2024-07-23_013545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-23_013545.